The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Inmunohistochemical expression of thymidilate synthase, ERCC1, pKDR, and LDH5 as predcitive markers of efficacy in patients with advanced colon cancer treated with XELOX or FOLFOX with or without bevacizumab.
Javier Garde
No relevant relationships to disclose
Elena Evgenyeva
No relevant relationships to disclose
Gil raga Mireia
No relevant relationships to disclose
Laia Bernet
No relevant relationships to disclose
Asuncion Juarez
No relevant relationships to disclose
Juan Laforga
No relevant relationships to disclose
Juan Manuel Gassent
No relevant relationships to disclose
Martin Demarchi
No relevant relationships to disclose
Carlos Camps
No relevant relationships to disclose
Antonio Llombart
No relevant relationships to disclose